1. Blik op de toekomst: lopende en geplande DOCG studies
Dr. Hanneke W.M. van Laarhoven
Medische Oncologie
Academisch Medische Centrum
Blik op de toekomst: lopende en geplande DOCG studies
Neoadjuvante chemoradiatie: surgery when needed (preSANO)
Neoadjuvante chemoradiatie: targeted treatment (TRAP)
Neoadjuvante/definitieve chemoradiatie: surgery if possible (TOR)
Definitieve chemoradiatie: dosisintensificatie (ART-DECO)
Dataregistratie (POCOP)

2. preSANO pre- Surgery As Needed for Oesophageal carcinoma
A single-arm feasibility trial
Primary endpoint
Correlation between the clinical response during CRE-I and CRE-II and the final pathological response in the resection specimen
Secondary endpoints
Serious complications during endoscopic and endosonographic tissue sampling
R0-resection rates for all included patients that undergo resection

3. A single arm feasibility study
TRAP
Chemoradiation, TRAstuzumab and Pertuzumab in resectable HER2+ esophageal carcinoma
A single arm feasibility study
Primary endpoint
Withdrawal rate from surgery
Secondary endpoints
pCR
Toxicity
Post-operative complications

4. TOR
Chemoradiotherapy followed by resection for patients with gevolgd a T4b oesofagus carcinoma
Primary endpoint
R0 resection (≥ 80% )
Secondary endpoints
Post-operative complications
Mortality
Quality of life

5. ART-DECO
A Randomized Trial of Dose Escalation in definitive Chemoradiotherapy for patients with Oesophageal cancer
Primary endpoint
Local recurrence rate (≥ 15% difference)
Secondary endpoints
Grade 3-4 toxicity
Survival
Landelijk Platform Radiotherapie voor Gastro Enterologische tumoren
Er doen nu 15 radiotherapie instituten mee (van de 21 RT instituten in NL). Voor 2 instituten loop de aanvraagprocedure nog. De overige instituten doen geen RT voor oesofagus. Geen wezenlijk toegenomen toxiciteit in boost arm tot zover. In MD Anderson is recent een bijna vergelijkbare studie gestart, doch met cisplatin\5 FU en alleen voor plaveiselcelcarc. Direct contact met hen loopt

6. POCOP Acknowledgments Prospective Observational Cohort Study of
Oesophageal-gastric cancer Patients
Acknowledgments
Joel Shapiro, Bas Wijnhoven, Jan van Lanschot (preSANO)
Maarten Anderegg, Mark van Berge Henegouwen (TOR)
Maarten Hulshof (ART-DECO)
Leonie Haverkamp, Jelle Ruurda (Oesofagus/maag parel)